ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements
Biogen Pharmachem Industries reported un-audited financial results for the quarter ended September 30, 2026. The company posted a net profit of Rs. 25.73 Lakhs for the period.
Biogen Pharmachem Industries Ltd intimated a board meeting on 3 November 2026 to approve unaudited results for Q2 and half year ended 30 September 2026. The filing is a meeting notice only, with no monetary event.
Rama Shiva Lease Finance disposed of all 4.26 crore Biogen Pharmachem shares in open market. The non-promoter now holds zero stake, fully exiting the company.
Biogen Pharmachem Industries Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI Regulation 31(1)(b).
Biogen Pharmachem Industries Limited held its 31st Annual General Meeting on 29th September 2026. Shareholders approved financial statements, director re-appointment, and the auditor appointment.
Biogen Pharmachem Industries Limited submitted its 31st Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 29, 2026.
Biogen Pharmachem Industries Ltd has issued a notice for its 31st Annual General Meeting scheduled for September 29, 2026. The meeting will be held via video conferencing.
Biogen Pharmachem Industries Limited has reported no unutilised funds from any prior capital raises, including public issues, rights issues, or preferential allotments, as of June 2026.
Biogen Pharmachem Industries Ltd reported revenue from operations of ₹0.4 Cr (-73.3% YoY) and net profit of ₹0.2 Cr (-84.6% YoY) for Q1 FY27.
Biogen Pharmachem Industries Limited scheduled a Board meeting for August 5, 2026. The meeting will consider and approve financial results for the quarter ended June 30, 2026.
Biogen Pharmachem Industries submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The company confirmed compliance with all applicable SEBI regulations and secretarial standards.
Interface Financial Services Limited sold a 4.47% stake in Biogen Pharmachem Industries through the open market. This reduces their total equity holding to 4.84%.
Biogen Pharmachem Industries allotted 15,04,33,833 bonus equity shares to eligible shareholders on May 18, 2026. The move increases paid-up capital through capitalisation of reserves.
Biogen Pharmachem Industries Ltd reported revenue from operations of ₹0.6 Cr (-57.1% YoY) and a net loss of ₹0.4 Cr for Q4 FY26.
Biogen Pharmachem Industries reported its audited FY2026 results with an annual total income of ₹2.56 Crore. The company posted a net profit of ₹0.86 Crore.
Biogen Pharmachem Industries Ltd has scheduled a Board of Directors meeting on May 14, 2026. The board will primarily consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026.
Biogen Pharmachem Industries Limited confirmed it does not fall under the 'Large Corporate' category as per SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144. Consequently, the company is exempt from mandatory borrowing requirements and initial disclosure obligations for the financial year ended March 31, 2026.
Biogen Pharmachem Industries submitted its quarterly certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar confirmed that no physical share certificates were received for dematerialization during the quarter. This is a routine compliance filing with no material impact on business operations.